Dechra Pharmaceuticals (DCHPF) Short Interest Ratio & Short Volume → What is the 72-Hour Profit Surge? (From DTI) (Ad) Free DCHPF Stock Alerts $46.90 0.00 (0.00%) (As of 01/18/2024) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Dechra Pharmaceuticals Short Interest DataCurrent Short Volume24,600 sharesPrevious Short Volume28,400 sharesChange Vs. Previous Month-13.38%Dollar Volume Sold Short$1.15 millionShort Interest Ratio / Days to Cover0.0Last Record DateJanuary 15, 2024Today's Trading Volume0 sharesAverage Trading Volume1,687 sharesToday's Volume Vs. Average0% Short Selling Dechra Pharmaceuticals ? Sign up to receive the latest short interest report for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatDCHPF Short Interest Over TimeDCHPF Days to Cover Over TimeDCHPF Percentage of Float Shorted Over Time Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << Dechra Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/15/202424,600 shares $1.15 million -13.4%N/A0 $46.90 12/31/202328,400 shares $1.33 million -3.4%N/A437 $46.90 12/15/202329,400 shares $1.38 million +3.5%N/A294 $46.90 11/30/202328,400 shares $1.33 million -6.0%N/A0 $46.90 11/15/202330,200 shares $1.42 million -1.0%N/A302 $47.00 10/31/202330,500 shares $1.43 million +3.0%N/A0 $47.00 Get the Latest News and Ratings for DCHPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/15/202329,600 shares $1.39 million No ChangeN/A0 $47.00 9/30/202329,600 shares $1.39 million -61.9%N/A74 $47.00 9/15/202377,600 shares $3.67 million +32.0%N/A86.2 $47.32 8/31/202358,800 shares $2.73 million +17.6%N/A0 $46.50 8/15/202350,000 shares $2.33 million -39.4%N/A0 $46.50 7/31/202382,500 shares $3.84 million -55.8%N/A0 $46.50 7/15/2023186,500 shares $8.67 million -40.4%N/A932.5 $46.50 6/30/2023312,900 shares $14.16 million +50.0%N/A0 $45.25 6/15/2023208,600 shares $9.44 million -2.3%N/A149 $45.25 5/31/2023213,500 shares $6.41 million -49.0%N/A0 $30.00 5/15/2023418,200 shares $12.55 million +24.0%N/A0 $30.00 4/30/2023337,400 shares $10.12 million +123.2%N/A3374 $30.00 4/15/2023151,200 shares $4.54 million -3.9%N/A1512 $30.00 3/31/2023157,400 shares $4.93 million No ChangeN/A1574 $31.35 3/15/2023157,400 shares $4.93 million -3.0%N/A787 $31.35 2/28/2023162,300 shares $6.02 million +2.9%N/A1623 $37.10 2/15/2023157,700 shares $5.81 million -52.4%N/A788.5 $36.84 1/31/2023331,100 shares $10.76 million +93.6%N/A1103.7 $32.50 1/15/2023171,000 shares $5.54 million -53.9%N/A1710 $32.40 12/30/2022370,900 shares $11.96 million +120.1%N/A1236.3 $32.25 12/15/2022168,500 shares $5.65 million -51.9%N/A1685 $33.55 11/30/2022350,600 shares $11.78 million +104.4%N/A0 $33.60 11/15/2022171,500 shares $5.76 million -4.6%N/A428.8 $33.60 10/31/2022179,800 shares $5.02 million +6.5%N/A1798 $27.90 10/15/2022168,900 shares $4.71 million -2.2%N/A1689 $27.90 9/30/2022172,700 shares $7.38 million +1.8%N/A1727 $42.75 9/15/2022169,600 shares $7.25 million -0.4%N/A1696 $42.75 8/31/2022170,300 shares $7.28 million +2.7%N/A340.6 $42.75 8/15/2022165,900 shares $7.09 million -0.8%N/A0 $42.75 7/31/2022167,200 shares $7.15 million -13.7%N/A1672 $42.75 7/15/2022193,700 shares $8.28 million +14.4%N/A1937 $42.75 6/30/2022169,300 shares $6.60 million +33.7%N/A0 $39.00 6/15/2022126,600 shares $4.94 million -9.2%N/A0 $39.00 5/31/2022139,400 shares $5.44 million +1.0%N/A0 $39.00The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. DCHPF Short Interest - Frequently Asked Questions What is Dechra Pharmaceuticals' current short interest? Short interest is the volume of Dechra Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of January 15th, traders have sold 24,600 shares of DCHPF short. Learn More on Dechra Pharmaceuticals' current short interest. Is Dechra Pharmaceuticals' short interest increasing or decreasing? Dechra Pharmaceuticals saw a decrease in short interest in January. As of January 15th, there was short interest totaling 24,600 shares, a decrease of 13.4% from the previous total of 28,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.10 billion), General Motors ($3.90 billion), Charter Communications, Inc. ($3.31 billion), Occidental Petroleum Co. ($2.91 billion), Tractor Supply ($2.75 billion), Moderna, Inc. ($2.44 billion), Coinbase Global, Inc. ($2.10 billion), United Rentals, Inc. ($2.09 billion), Royal Caribbean Cruises Ltd. ($2.03 billion), and Rivian Automotive, Inc. ($1.89 billion). View all of the most shorted stocks. What does it mean to sell short Dechra Pharmaceuticals stock? Short selling DCHPF is an investing strategy that aims to generate trading profit from Dechra Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Dechra Pharmaceuticals? A short squeeze for Dechra Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DCHPF, which in turn drives the price of the stock up even further. How often is Dechra Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DCHPF, twice per month. The most recent reporting period available is January, 15 2024. More Short Interest Resources from MarketBeat Related Companies: AstraZeneca Short Interest Data CSPC Pharmaceutical Group Short Interest Data Daiichi Sankyo Short Interest Data JCR Pharmaceuticals Short Interest Data Kyowa Kirin Short Interest Data Mayne Pharma Group Short Interest Data Ono Pharmaceutical Short Interest Data Orion Oyj Short Interest Data Otsuka Short Interest Data Otsuka Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:DCHPF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings